NB100-97821
antibody from Novus Biologicals
Targeting: KDM5B
CT31, JARID1B, PLU-1, PPP1R98, RBBP2H1A
Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [3]
- Immunoprecipitation [1]
- Immunohistochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NB100-97821 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NB100-97821, RRID:AB_1291176
- Product name
- Rabbit Polyclonal Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 ul
- Concentration
- 1.0 mg/ml
- Storage
- Store at 4C. Do not freeze.
Submitted references Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma.
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Webster MR, Fane ME, Alicea GM, Basu S, Kossenkov AV, Marino GE, Douglass SM, Kaur A, Ecker BL, Gnanapradeepan K, Ndoye A, Kugel C, Valiga A, Palmer J, Liu Q, Xu X, Morris J, Yin X, Wu H, Xu W, Zheng C, Karakousis GC, Amaravadi RK, Mitchell TC, Almeida FV, Xiao M, Rebecca VW, Wang YJ, Schuchter LM, Herlyn M, Murphy ME, Weeraratna AT
Molecular cell 2020 Feb 6;77(3):633-644.e5
Molecular cell 2020 Feb 6;77(3):633-644.e5
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.
Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A
European journal of cancer (Oxford, England : 1990) 2019 Mar;109:137-153
European journal of cancer (Oxford, England : 1990) 2019 Mar;109:137-153
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.
Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A
The Journal of investigative dermatology 2019 Dec;139(12):2506-2516.e10
The Journal of investigative dermatology 2019 Dec;139(12):2506-2516.e10
CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
Boyle SE, Fedele CG, Corbin V, Wybacz E, Szeto P, Lewin J, Young RJ, Wong A, Fuller R, Spillane J, Speakman D, Donahoe S, Pohl M, Gyorki D, Henderson MA, Johnstone RW, Papenfuss AT, Shackleton M
Cancer research 2016 Jul 1;76(13):3965-77
Cancer research 2016 Jul 1;76(13):3965-77
SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.
Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, Ballard BR, Nakayama KI, Matusik RJ, Chen Z
Oncotarget 2015 Jan 20;6(2):771-88
Oncotarget 2015 Jan 20;6(2):771-88
Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.
Stanisz H, Saul S, Müller CS, Kappl R, Niemeyer BA, Vogt T, Hoth M, Roesch A, Bogeski I
Pigment cell & melanoma research 2014 May;27(3):442-53
Pigment cell & melanoma research 2014 May;27(3):442-53
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M
Cancer cell 2013 Jun 10;23(6):811-25
Cancer cell 2013 Jun 10;23(6):811-25
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and NIH3T3 (M; 50 mcg) cells. NB100-97821 used for WB at 0.1 mcg/ml (A) and 1 mcg/ml (B) and used for IP at 3 mcg/mg lysate.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - Detection of Human and Mouse Jarid1B by Western Blot. Samples: Whole cell lysate (50, 15, 5 ug) from 293T and (50 ug) HeLa and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-Jarid1B antibody NB100-97821 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - Whole cell lysate (50 ug) from HeLa, 293T, and Jurkat cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-JARID1B antibody used for WB at 0.4 ug/ml. Detection: Chemiluminescence with an exposure time of 3 minutes.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunoprecipitation: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - Detection of human JARID1B by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from 293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-JARID1B antibody NB100-97821 (lot NB100-97821-3) used for IP at 6 ug per reaction. JARID1B was also immunoprecipitated by a previous lot of this antibody (lot NB100-97821-2). For blotting immunoprecipitated Jarid1B, NB100-97821 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 75 seconds.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - FFPE section of human prostate carcinoma. Antibody: Affinity purified rabbit anti-Jarid1B used at a dilution of 1:500 (2ug/ml). Detection: DAB
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - MCF-7 cells stained with Lysine (K)-specific Demethylase 5B antibody. Image from verified customer review.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: Lysine (K)-specific Demethylase 5B/KDM5B/JARID1B Antibody [NB100-97821] - Section of human prostate carcinoma. Antibody: Rabbit anti-JARID1B antibody used at 1:500 (2ug/ml). Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.